Posting of Annual report & Notice of AGM
RNS Number : 9721Z
Verona Pharma PLC
20 March 2017
Verona Pharma plc
("Verona Pharma" or the "Company")
2016 Annual Report and Accounts
and
Notice of AGM
20 March 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended 31 December 2016 ("2016 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been posted to Shareholders.
The Company confirms that its 2016 Annual Report and Accounts are available online at: http://www.veronapharma.com/investors/#investors-financial-performance. The Notice of Annual General Meeting can be found within the AIM Rule 26 section of the website.
The Annual General Meeting of Verona Pharma will be held at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London EC3V 0HR on 12th April 2017 at 12.00 noon.
-Ends-
For further information please contact:
|
|
Notes to Editors
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti‑inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKMGZFFGMGNZM
